Targeting Hormone-Sensitive Cancers

AndroBioSys is a bio-pharmaceutical company focused on:

  • Advanced prostate disease imaging and therapeutics
  • The discovery and development of drugs for the treatment of prostate disease and other hormone-sensitive cancers, and
  • Contract research for academic, biotechnology and pharmaceutical clients.

Latest News

Top Headline

Seven teams seek to convert high-tech ideas into start-ups
Entrepreneurs receive feedback from experts on business plans at end of 3-day workshop

Buffalo News
Published: June 22, 2011
By Stephen T. Watson

Every business starts with an idea, but it’s a long way from the moment of inspiration to becoming a Google or a General Motors.
Prospective entrepreneurs...

Read More...

ABS Awarded More Than $2 Million in New Federal Funds
AndroBioSys, Inc. (ABS) has been awarded more than $2 million in new federal funds from three independent sources in the past six months. The largest award is a two-year, $1 million Small Business Innovation Research “Phase Two” contract from the National Cancer Institute that will support a project focusing on prostate cancer imaging and therapeutics.

Read More...

Oishei Makes First Bio-medical Investment (from Business First: May 17, 2010)
A $200,000 investment in a Buffalo biomedical firm represents the first equity investment by the John R. Oishei Foundation. But the investment in AndroBioSys Inc. won’t likely be the last such investment by Oishei as the private foundation continues to explore additional mission-related investment opportunities in the region.

Read More...

AndroBioSys Secures $500K

From Business First: January 12, 2009
Just months after receiving two federal research grants, a Buffalo bioscience firm has closed on a $500,000 round of funding from local investors.AndroBioSys Inc. received the funding from a combination of sources, including local angel investors associated with the WNY Venture Association, the Erie County Industrial Development Agency and Excell Partners,...

Read More...